EPHA2 and prostate carcinoma: In the PC3 human prostate cancer cell line, EphA2 coimmunoprecipitated with EphB2 via the ligand binding domain, showing a co-clustering of these receptors that may differentially affect the Eph-ephrin signaling landscape based on the present heteromers (53).